Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2080 clinical trials
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy alone.

recurrent nasopharyngeal carcinoma
creatinine clearance rate
toripalimab
recurrent nasopharyngeal cancer
adjuvant
  • 0 views
  • 05 Aug, 2020
Safety of Liposom With Citalopram in Elderly Patients With Major Depressive Disorder

The purpose of this study is to determine if Liposom Forte will enhance the response to antidepressant therapy with citalopram in elderly patients suffering from Major Depressive Disorder (MDD).

  • 0 views
  • 11 Oct, 2021
  • 16 locations
A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

neutrophil count
apatinib
MRI
hepatocellular carcinoma
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
iACT for PTSD and Chronic Pain Website

The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for PTSD and comorbid chronic pain using a randomized controlled trial with waitlist control.

  • 0 views
  • 05 Nov, 2025
  • 19 locations
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

The use of targeted therapy against VEGF can not only inhibit tumor neovascularization, but also make the effectiveness of chemotherapeutic agents. VEGF and VEGFR are closely related to immune escape.

neovascularization
apatinib
vascular endothelial growth factor
angiogenesis
carcinoma
  • 0 views
  • 05 Aug, 2020
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1 previous therapy

measurable disease
systemic therapy
non-resectable cholangiocarcinoma
FGFR2
pemigatinib
  • 0 views
  • 16 Feb, 2024
  • 1 location
Microbiome and Rectal Cancer

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

adjuvant therapy
rectal cancer
neoadjuvant therapy
chemoradiotherapy
cancer
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A tolerable safety profile and demonstrated efficacy would support a potential, randomized phase 3 trial comparing the experimental combination therapy and standard of care intravesical BCG therapy.

bladder cancer
luteinizing hormone
transitional cell carcinoma
bacillus calmette-guerin
follicle stimulating hormone
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.

measurable disease
lenvatinib
hepatocellular carcinoma
carcinoma
  • 0 views
  • 05 Aug, 2020
Extension Study of Carvedilol RCT Study

Patients who have completed 2-years treatment in RCT Study of carvedilol will receive another 2-years extension therapy, aiming to investigate the long-term efficacy of carvedilol for the prevention of esophageal varices in treated HBV cirrhotic patients.

  • 0 views
  • 26 Aug, 2021
  • 13 locations